These findings mirror our results, demonstrating a significant improvement in therapeutic efficacy seen with NDV-ICOSL, likely explained by the preferential effect of ICOSL on expansion and effector function of the tumour-infiltrating CD8+ and conventional CD4+ T cells. This evidence concerns the gene ICOSLG and neoplasm.